Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

BACKGROUND: Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase II IMvigor210 study demonstrated the efficacy and safety of atezolizumab, a programmed death-ligand 1-directed antibody, in patien...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Necchi, A, Joseph, R W, Loriot, Y, Hoffman-Censits, J, Perez-Gracia, J L, Petrylak, D P, Derleth, C L, Tayama, D, Zhu, Q, Ding, B, Kaiser, C, Rosenberg, J E
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834063/
https://ncbi.nlm.nih.gov/pubmed/28950298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx518
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki